Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 99(51): e23759, 2020 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-33371138

RESUMO

BACKGROUND: Xinyin Tablet (XYT) has been widely used in the treatment of CHF, Which helping to improve the clinical symptoms, enhance exercise, and even may improve the long-term prognosis of patients. However, the exact effectiveness and safety of XYT for CHF has not be comprehensively researched, so we want to generalize the effectiveness and safety of XYT for CHF through the meta-analysis, which may benefit the design of future clinical trials and provide valuable references. METHODS: This protocol complies with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols. From the inception until September 2020, a systematic and comprehensive electronic search about Relevant randomized controlled trials will be conducted in 4 English literature databases and 4 Chinese literature databases. The registration number: INPLASY2020100015. 2 investigators will be arranged to deal with the study selection and data extraction independently. The New York Heart Function Classification, traditional Chinese medicine (TCM) symptom scores, the scores of quality of life, 6-min walk distance (6MWD), etc. will be systematically measured as outcomes. At last, the data will be handled by Review Manager 5.3 and Stata 15.0. RESULTS AND CONCLUSION: This study is hoping to provide a high-level evidence to prove the therapeutic effect of XYT on CHF, which may enhance the application of Chinese medicine.


Assuntos
Protocolos Clínicos , Insuficiência Cardíaca/tratamento farmacológico , Medicina Tradicional Chinesa/normas , Insuficiência Cardíaca/fisiopatologia , Humanos , Medicina Tradicional Chinesa/métodos , Medicina Tradicional Chinesa/tendências , Metanálise como Assunto , Peptídeo Natriurético Encefálico/análise , Qualidade de Vida/psicologia , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Revisões Sistemáticas como Assunto , Ultrassonografia/métodos
2.
Exp Lung Res ; 41(1): 12-20, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25275819

RESUMO

The aim of the study was to investigate the effects of substance P (SP) in hyperoxia-induced lung injury in newborn rats. Thirty-two rat pups were randomly divided into four groups: normoxia/saline, normoxia/SP, hyperoxia/saline and hyperoxia/SP. In a separate set of experiments, the neonatal rat pups were exposed to 21% or >95% O2 for 14 days with or without intraperitoneal administration of SP. On day 14, the animals were sacrificed and the lungs were processed for histology and biochemical analysis. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was used for the detection of apoptosis. Antioxidant capacity was assessed by glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD), oxidative stress was assessed by determining the extent of formation of malondialdehyde (MDA), activities of NADPH oxidase activity, and formation of reactive oxygen species (ROS). The activity of phospho-p38 (p-p38) and -ERK1/2 (p-ERK1/2) proteins and expression of NF-E2-related factor 2 (NRF2) were detected by Western blot, and the expression of p-p38 was detected by immunofluorescence analysis. Compared with the hyperoxia treatment, the lung damage was significantly ameliorated following the SP treatment. Furthermore, the lungs from the pups exposed to hyperoxia TUNEL-positive nuclei increased markedly and decreased significantly after SP treatment. The levels of MDA decreased and that of GSH-Px and SOD increased following the SP treatment. The SP treatment significantly suppressed the activity of NADPH oxidase and reduced ROS production. SP stimulation may result in blocking p38 MAPK and ERK signaling pathways, and the activities of p-p38 and p-ERK, and expression of NRF2 decreased following the SP treatment. These findings indicate that SP can ameliorate hyperoxic lung injury through decreasing cell apoptosis, elevating antioxidant activities, and attenuating oxidative stress.


Assuntos
Displasia Broncopulmonar/prevenção & controle , Hiperóxia/complicações , Neurotransmissores/uso terapêutico , Substância P/uso terapêutico , Animais , Animais Recém-Nascidos , Displasia Broncopulmonar/enzimologia , Displasia Broncopulmonar/etiologia , Avaliação Pré-Clínica de Medicamentos , Edema/etiologia , Edema/prevenção & controle , Ativação Enzimática/efeitos dos fármacos , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Feminino , Glutationa Peroxidase/metabolismo , Hiperóxia/enzimologia , Pulmão/enzimologia , Malondialdeído/metabolismo , Fator 2 Relacionado a NF-E2/metabolismo , Neurotransmissores/farmacologia , Gravidez , Distribuição Aleatória , Ratos Sprague-Dawley , Substância P/farmacologia , Superóxido Dismutase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA